NCT07334054

Brief Summary

Muscle fatigue caused by physical training is understood as a condition related to the inability to maintain action potential, derived from the alteration in skeletal muscle homeostasis. In long-distance recreational runners, prolonged physical work is performed while maintaining the level of intensity, where a level of fatigue intervenes, which overlaps and generates tiredness to execute the movement continuously. In the last 10 years, sports supplementation has been explored as an aid to increase physical performance, improve muscle recovery and prevent sports injuries.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
64

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 17, 2025

Completed
2 months until next milestone

Study Start

First participant enrolled

January 1, 2026

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 12, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2026

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2026

Completed
Last Updated

January 12, 2026

Status Verified

January 1, 2026

Enrollment Period

3 months

First QC Date

November 17, 2025

Last Update Submit

January 5, 2026

Conditions

Outcome Measures

Primary Outcomes (6)

  • Changes in lactate levels compared to the placebo group

    mMol/L

    8 weeks

  • Changes in interleukin-6 levels compared to the placebo group

    pg/ml

    8 weeks

  • Changes in cratine kinase levels compared to the placebo group

    U/L

    8 weeks

  • Changes in testosterone cortisol ratio compared to the placebo group

    mcg/dL

    8 weeks

  • Changes in maximal aerobic speed compared to the placebo group

    km/h

    8 weeks

  • Changes in maximal oxygen consumption compared to the placebo group

    ml.O2.kg/min

    8 weeks

Study Arms (4)

Group 1 (TP + BCAA + VitD)

EXPERIMENTAL

Training Program + Branched-Chain Amino Acids + Vitamin D

Other: Training programDietary Supplement: Branched-Chain Amino AcidsDietary Supplement: Vitamin D

Group 2 (TP + BCAA + P2)

EXPERIMENTAL

Training Program + Branched-Chain Amino Acids + Placebo 2

Other: Training programDietary Supplement: Branched-Chain Amino AcidsOther: Placebo 2

Group 3 (TP + VitD + P1)

EXPERIMENTAL

Training Program + Vitamin D (1000 IU) + Placebo 1

Other: Training programDietary Supplement: Vitamin DOther: Placebo 1

Group 4 (TP + P1+ P2)

PLACEBO COMPARATOR

Training Program + Placebo1 + Placebo 2

Other: Training programOther: Placebo 1Other: Placebo 2

Interventions

Vitamin DDIETARY_SUPPLEMENT

Vitamin D (1000 IU/day)

Also known as: VitD
Group 1 (TP + BCAA + VitD)Group 3 (TP + VitD + P1)

Aerobic training program (60-90% of maximum aerobic speed)

Also known as: TP
Group 1 (TP + BCAA + VitD)Group 2 (TP + BCAA + P2)Group 3 (TP + VitD + P1)Group 4 (TP + P1+ P2)
Branched-Chain Amino AcidsDIETARY_SUPPLEMENT

Branched-chain amino acids (5 gr/day)

Also known as: BCAA
Group 1 (TP + BCAA + VitD)Group 2 (TP + BCAA + P2)

Placebo 1 (5gr/day)

Also known as: P1
Group 3 (TP + VitD + P1)Group 4 (TP + P1+ P2)

Placebo 2 (1 tablet/day)

Also known as: P2
Group 2 (TP + BCAA + P2)Group 4 (TP + P1+ P2)

Eligibility Criteria

Age25 Years - 44 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Adults aged 25 to 44
  • Men
  • Agree to participate in the study
  • Sign a consent form
  • Experience in long-distance running

You may not qualify if:

  • Have a previous diagnosis of liver disease, asthma, hypertension, diabetes, cancer, anemia
  • Have a previous diagnosis of a neurological disorder (Alzheimer's disease, Parkinson's disease, epilepsy)
  • Have a musculoskeletal disability
  • Be on medication or supplementation
  • Hypervitaminosis D (\>100 ng/mL)
  • Be on a structured training program
  • Use anabolic steroids

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universidad de Colima

Colima, Colima, 28040, Mexico

Location

Related Publications (2)

  • Howatson G, Hoad M, Goodall S, Tallent J, Bell PG, French DN. Exercise-induced muscle damage is reduced in resistance-trained males by branched chain amino acids: a randomized, double-blind, placebo controlled study. J Int Soc Sports Nutr. 2012 Jul 12;9:20. doi: 10.1186/1550-2783-9-20. eCollection 2012.

    PMID: 22569039BACKGROUND
  • Zebrowska A, Sadowska-Krepa E, Stanula A, Waskiewicz Z, Lakomy O, Bezuglov E, Nikolaidis PT, Rosemann T, Knechtle B. The effect of vitamin D supplementation on serum total 25(OH) levels and biochemical markers of skeletal muscles in runners. J Int Soc Sports Nutr. 2020 Apr 9;17(1):18. doi: 10.1186/s12970-020-00347-8.

    PMID: 32272973BACKGROUND

MeSH Terms

Interventions

Amino Acids, Branched-ChainVitamin DP-2

Intervention Hierarchy (Ancestors)

Amino AcidsAmino Acids, Peptides, and ProteinsSecosteroidsSteroidsFused-Ring CompoundsPolycyclic Compounds

Study Officials

  • Pedro J Flores Moreno, Doctor of Medical Sciences

    Universidad de Colima

    STUDY DIRECTOR

Central Study Contacts

MarĂ­a Zepeda Fuentes, Master of Medical Sciences

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
The research is categorized as double-blind parallel groups, the study subjects will be blinded, by not recognizing that they are under supplementation and secondly the principal investigator will also be unaware of the assigned treatment.
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: In clinical trial types based on their methodology, this protocol is considered a randomized controlled clinical trial. Based on the behavior of its groups, the research is categorized as a parallel group.
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Doctor of Medical Sciences

Study Record Dates

First Submitted

November 17, 2025

First Posted

January 12, 2026

Study Start

January 1, 2026

Primary Completion

March 30, 2026

Study Completion

June 1, 2026

Last Updated

January 12, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will share

Results and analysis will be shared with other researchers collaborating on the research project.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE

Locations